New hope for PSP: experimental Vaccine-Like drug enters key trial
NCT ID NCT07217665
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests a drug called AADvac1 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. The goal is to see if AADvac1 can slow down the disease. About 146 participants with early-stage PSP will receive the drug or a placebo, and researchers will track changes in symptoms over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSP - PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.